CAJ | 학술논문

以嵌合型抗原受体（chimeric antigen receptor，CAR）为基础的细胞免疫治疗是一种新的治疗恶性肿瘤的模式，为部分晚期实体瘤患者带来治愈的希望。选择合适的目标靶分子、应用安全的基因转导方法、防治CAR-T细胞治疗的不良反应、将使CAR-T细胞造福越来越多的晚期肿瘤患者。
이감합형항원수체（chimeric antigen receptor，CAR）위기출적세포면역치료시일충신적치료악성종류적모식，위부분만기실체류환자대래치유적희망。선택합괄적목표파분자、응용안전적기인전도방법、방치CAR-T세포치료적불량반응、장사CAR-T세포조복월래월다적만기종류환자。
Adoptive cell transfusion based on chimeric antigen receptor (CAR) is a new approach for treating malignant diseases and even advanced malignancies. More patients with advanced malignancies are expected to benefit from CAR T-cells once the suitable target molecules are selected, the safe method of gene transduction is applied, and the side effects of CAR T-cells are prevented.